Polarean Imaging plc (AIM: POLX), the medical imaging technology company, with a proprietary drug?device combination product for the magnetic resonance imaging (MRI) market, notes that its partner company Amphion Innovations plc (“Amphion”), has pledged its holding of 18,372,523 shares in Polarean as additional security against its loan facility with its debt provider (the “Lender”).
Polarean Imaging plc (AIM: POLX), the medical imaging technology company, with a proprietary drug?device combination product for the magnetic resonance imaging (MRI) market, notes that its partner company Amphion Innovations plc (“Amphion”), has pledged its holding of 18,372,523 shares in Polarean as additional security against its loan facility with its debt provider (the “Lender”).
Amphion has transferred the legal title to, but retains the beneficial interest in, the pledged shares in Polarean. In addition, the Lender has agreed to adhere to the terms of an orderly market agreement for the next 12 months with regards to the 18,372,523 Polarean shares.
The full announcement from Amphion is available here http://www.rns-pdf.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
Enquiries:
Polarean Imaging plc
www.polarean.com / www.
Richard Hullihen, Chief Executive Officer
Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP
Tel: +44 (0)20 3470 0470
David Hignell
Lindsay Mair
MC Services (European IR)
Tel: +49 (0)89 210 2280
Raimund Gabriel
Walbrook PR
Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy
Helen Cresswell
Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001
Mob: +44 (0)7841 917 679
